AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 28th, 2014 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Amendment to Asset Purchase Agreement, dated as of October 21, 2013 (the “Amendment”), is entered into by and between NOVEL DRUG SOLUTIONS LLC, a New Jersey limited liability company (“NDS”) and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis” and together with NDS, the “Parties”, and each, a “Party”).
ASSET PURCHASE AGREEMENTConfidential Treatment • March 28th, 2014 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of October 8, 2013 (the “Effective Date”), is entered into between NOVEL DRUG SOLUTIONS, LLC, a New Jersey limited liability company (“Seller”), with a place of business at 540 State Route 10, Suite 3, Randolph, NJ 07869, and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), with a place of business at 12626 High Bluff Drive, Suite 150, San Diego, California 92130. The parties hereby agree as follows:
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 28th, 2014 • Imprimis Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amendment to Asset Purchase Agreement, dated as of October 21, 2013 (the “Amendment”), is entered into by and between BUDERER DRUG COMPANY, INC., an Ohio corporation (“Buderer”), with a place of business at 633 Hancock Street, Sandusky, Ohio 44870), and IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis” and together with Buderer, the “Parties”, and each, a “Party”).
